Read More Pharma Industry News Why Celcuity’s FDA priority review for gedatolisib could reset the breast cancer playbook Celcuity earns FDA priority review for gedatolisib in advanced breast cancer. Find out what the July 2026 PDUFA date means for its market trajectory. byPallavi MadhirajuJanuary 21, 2026